CARY, N.C.—Calvert Holdings Inc. is setting up a Calvert BioCapital Fund, a venture capital limited partnership that will acquire and develop early stage biopharmaceutical compounds and technologies. (more…)
RALEIGH, NC – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) seeking approval to market a 1100 milligram tablet formulation of balsalazide disodium (balsalazide tablet). (more…)
Atlanta, GA– Southeast BIO (SEBIO) has elected four new members to its Board of Directors to lead the organization. The new members of SEBIO’s Board of Directors include Thomas Brooks, HealthCare Capital Partners; David L. Brumfield, Smith & Nephew; Gerard van Hamel Platerink, Accuitive Medical Ventures; Stephen Snowdy, MB Venture Partners. (more…)
ATLANTA, GA–Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that it has acquired an innovative head lice asphyxiation product developed by Summers Laboratories, Inc. for the United States, Canada and Mexico. (more…)
RALEIGH, NC—Micell Technologies, a biomedical company developing new ways to deliver drugs via medical devices such as stents, has raised $7 million from Invemed Catalyst Fund and GE Pension Plan. (more…)
ATLANTA–Sciele Pharma, Inc. (NASDAQ: SCRX) today announced that it has signed an exclusive agreement with Addrenex Pharmaceuticals, Inc. to market, upon approval by the U.S. Food & Drug Administration (FDA), CLONICEL(R), a patented, sustained-release formulation of clonidine hydrochloride for the treatment of hypertension and attention deficit and hyperactivity disorder in North America. (more…)
ATLANTA—Tikvah Thearapeutics, which is commercializing treatments for central nervous system diseases that it reformulates from existing FDA-approved compounds, has raised a $10 million bridge financing, according to Dow Jones’ Venture Wire.
(more…)
By Rebecca J. Kaufman
The promise of stem cell technology has generated more than a few headlines. So too have the politics of stem cells, namely human embryonic stem cells (hESC). As recently as last week, President Bush vetoed a bill that would have authorized expanded federal support for hESC research, citing moral issues. In the absence of new legislation, federal funding is limited to research on hESC lines derived before August 9, 2001; which many researchers have argued are inadequate. (more…)
ATHENS, GA—Abeome Corp., an Athens-GA-based biotech company commercializing monoclonal antibodies, has raised $350,000 of a $1.5 million in-progress seed round from Georgia Venture Partners and ATDC Seed Capital Fund.
(more…)
Acquisition Offers Self-Supporting Marketing & Sales Infrastructure Plus High-Potential Late-Stage Product Pipeline
Miami, FL– Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that it has agreed to acquire JDS Pharmaceuticals, LLC for approximately $125 million cash at closing plus the assumption of approximately $10 million in net liabilities. Based in New York City, JDS is a privately-held specialty pharmaceutical company that currently markets two branded prescription psychiatry products through a targeted sales force and is advancing a significant pipeline of high-potential products in psychiatry and women’s health.
(more…)
